Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Advances in Skin Cancer Diagnostics and Therapy: Research and Clinical...
cancers-logo
Submit to Cancers Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances in Skin Cancer Diagnostics and Therapy: Research and Clinical Studies (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (31 October 2025) | Viewed by 1929

Special Issue Editor

Dr. Cristel Ruini

E-Mail
Guest Editor
Department of Dermatology and Allergy, University Hospital, LMU Munich, 80336 Munich, Germany
Interests: dermatology; dermatosurgery; dermato-oncology; melanoma and non-melanoma skin cancer; non-invasive diagnostics in dermatology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the previous one, entitled “Advances in Skin Cancer Diagnostics and Therapy: Research and Clinical Studies” (https://www.mdpi.com/journal/cancers/special_issues/R64Q4G0HWR).

Skin cancer remains a significant global health concern. Not only melanoma but also less deadly non-melanoma skin cancers (NMSCs) continue to increase in incidence in the general population and pose challenges in terms of both research and clinical practice. In this Special Issue, we aim to bring together leading experts in the field of skin cancer and its diagnostic methods to share their groundbreaking findings. These articles should mainly focus on the ever more important connection of novel diagnostic tools, clinical applications, and artificial intelligence in a multidisciplinary context. Thank you for joining us on this journey where we aim to provide readers with a comprehensive overview of the latest advancements in this field.

Dr. Cristel Ruini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-melanoma skin cancer
  • melanoma
  • actinic keratosis
  • field cancerisation
  • medical diagnostics
  • dermatology
  • dermoscopy
  • optical coherence tomography
  • in vivo confocal microscopy
  • ex vivo confocal microscopy
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1056 KB  
Article
Clinical Olsen Grading Does Not Reflect Basal Growth in Actinic Keratoses: Two-Center Retrospective Analysis
by Lutz Schmitz, Conrad Falkenberg, Julius Balkenhol, Paul Melzer, Wolfgang G. Philipp-Dormston and Thomas Dirschka
Cancers 2025, 17(23), 3794; https://doi.org/10.3390/cancers17233794 - 27 Nov 2025
Viewed by 189
Abstract
Background/Objectives: Actinic keratosis (AK) is a precancerous lesion that may progress into cutaneous cancer. However, the progression potential of individual lesions remains unpredictable. The histological basal proliferation pattern of AKs may serve as a risk marker for progression, yet it cannot be [...] Read more.
Background/Objectives: Actinic keratosis (AK) is a precancerous lesion that may progress into cutaneous cancer. However, the progression potential of individual lesions remains unpredictable. The histological basal proliferation pattern of AKs may serve as a risk marker for progression, yet it cannot be assessed clinically. The objective was to evaluate whether Olsen grading (hyperkeratosis of AKs) and pain as clinical markers correlate with the histological basal proliferation (PRO) and different histological aspects. Methods: In this retrospective two-center study, 380 clinically diagnosed AKs were graded according to the clinical Olsen classification (I–III) and assessed for pain upon palpation. Histologically, they were classified based on their basal- (PRO I–III) and upward-directed (AK I–III) growth patterns, and additional histopathological features, such as acantholysis, were documented. Results: Olsen grading showed weak correlation with the PRO classification (Spearman’s rho = 0.136, p = 0.008), with exact agreement of 36.3% (κ = 0.07). Pain was significantly associated with higher PRO grades (p = 0.005) and acantholysis (p = 0.023) but not with Olsen grades or upward-directed growth (AK I–III). Conclusions: Olsen grading does not allow reliable prediction of basal proliferation patterns in AKs. Its use as a clinical severity scale may suggest progression relevance; however, no substantiated association with histological indicators of transformation could be demonstrated in this study. The presence of pain, however, correlated with high PRO grades and the presence of acantholysis. Full article
(This article belongs to the Special Issue Advances in Skin Cancer Diagnostics and Therapy: Research and Clinical Studies (2nd Edition))
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 257 KB  
Review
Predictive Factors for Sentinel Lymph Node Positivity in Melanoma Patients—The Role of Liquid Biopsy, MicroRNA and Gene Expression Profile Panels
by Federico Venturi, Elisabetta Magnaterra, Biagio Scotti, Manuela Ferracin and Emi Dika
Cancers 2025, 17(8), 1281; https://doi.org/10.3390/cancers17081281 - 10 Apr 2025
Cited by 3 | Viewed by 1406
Abstract
The identification of predictive factors for sentinel lymph node (SLN) positivity in melanoma patients is crucial for accurate staging, prognosis, and personalized therapeutic decisions. This review synthesizes recent advancements in molecular and clinicopathological predictors, with a particular focus on liquid biopsy and gene [...] Read more.
The identification of predictive factors for sentinel lymph node (SLN) positivity in melanoma patients is crucial for accurate staging, prognosis, and personalized therapeutic decisions. This review synthesizes recent advancements in molecular and clinicopathological predictors, with a particular focus on liquid biopsy and gene expression profiling (GEP) tools. Emerging evidence highlights the significant role of miRNAs in melanoma progression, metastatic potential, and lymphatic spread. Clinicopathological factors such as Breslow thickness, ulceration, and mitotic rate remain critical, while GEP provides additional precision by uncovering tumor-specific molecular pathways. By integrating these tools, clinicians can improve risk stratification, reduce unnecessary procedures, and personalize management strategies. Full article
(This article belongs to the Special Issue Advances in Skin Cancer Diagnostics and Therapy: Research and Clinical Studies (2nd Edition))
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop